Insights
We offer personalized insights and strategy, and spotlight data in a compelling way to shape policy, communicate value, secure reimbursement, and drive patient access.
-
Using Data-Driven Coverage Assessments to Unlock Medicare Part D Formulary Intelligence
Formulary coverage assessments are a critical component of successful market access strategies. As payer policies grow more complex and cost-containment tactics become more aggressive, pharmaceutical manufacturers must stay ahead of how coverage decisions impact product access, prescriber behavior, and ultimately, patient outcomes.
-
Decoding the 2025 Medicare Shifts: Key Insights for Pharma Market Access with Parker Edman
With the recent release of the 2025 Medicare plan enrollment data, pharma manufacturers must address significant shifts in the Part D prescription drug plan market, that could impact market access, formulary positioning, and patient affordability. We spoke with Parker Edman about the trends, challenges, and what manufacturers should prioritize to stay ahead.
-
Prescription Drug Affordability Boards: Considerations to Ensure Patient Access
The issue brief explores the PORTAL toolkit for Prescription Drug Affordability Boards (PDABs), highlighting key concerns and potential impacts on drug pricing, patient access, and policy implementation.
-
How The 340B Program Impacts Federal & State Tax Liability
While the 340B drug pricing program is often touted as cost-free to taxpayers, our analysis estimates the tax impact of the program for both self- and fully insured employees and workers across the US.
-
Measuring Drug Price Changes Through the Lens of Inflation
A data analysis comparing growth rates of US inflation and Medicare Part B drug prices (2015-2022) reveals that average sales price (ASP) has grown slower than inflation, making it a more transparent and relevant metric than list prices for evaluating medical spending trends.
-
Issue Brief: Federal-Level Policy Solution to Reduce Costs for 340B Patients
Magnolia Market Access analyzed a potential sliding fee scale policy, adjusting patient cost-sharing for 340B-dispensed drugs, to understand implications on out-of-pocket costs for 340B patients.
-
Issue Brief: State-Level Policy Solution to Reduce Costs for 340B Patients
Magnolia Market Access analyzed a potential sliding fee scale policy, adjusting patient cost-sharing for 340B-dispensed drugs, to understand implications on out-of-pocket costs for 340B patients.
-
Building a Comprehensive Go-To-Market Strategy Through Stakeholder Ecosystem Mapping
A mid-size client was preparing for a product launch and needed assistance facilitating a successful go-to-market strategy. The company sought to identify and understand the entire stakeholder landscape and create short- and long-term stakeholder engagement strategies to meet the needs of their entire organization.
-
Market Access Segmentation & Identification
A biopharma company engaged Magnolia Market Access and sister company, 81qd, to collect data and segment provider and payer entities to identify key decision makers for a novel cardiology treatment.
-
Using EMR Data to Support Budget Impact Modeling
A large pharmaceutical company needed to demonstrate the potential cost savings of placing a new drug on payer formularies.
-
Calculating Adherence in the Presence of Variable Follow-Up
A small-size pharmaceutical company was interested in using real-world evidence to compare adherence between two formulations of an oral oncology treatment for Multiple Myeloma (MM).
-
Using Real-world Data to Support Product Label Change
A mid-size pharmaceutical company was interested in obtaining real-world evidence demonstrating the safety and effectiveness of higher dosage chemotherapy for a labeled oncology indication.